Attorney pocket po. 20028

IN THE UNITED STATES PATENT AND TRADEMARK OFFI

In re Application of:

Saito et al.

Application No. 09/706,301

Filed: November 3, 2000

For: OIL ADJUVANT VACCINE

PEB 0 7 2001 CO

Group Art Unit: 1645

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In re Appln. of Saito et al. Application No. 09/706,301

	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:				
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).			
		the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).			
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).				
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.				
Copi		References			
	Copies of the references listed on the enclosed Form 1449 are enclosed herew Attached to each reference not in the English language is a concise explanation of relevance pursuant to 37 CFR 1.98(a)(3).				
		by of the foreign search report is enclosed herewith.			
	paren furnis subm The accor Proce	references listed on the enclosed Form 1449 were previously identified in the tapplication(s) of the present application, and copies of the references were shed at that time. Accordingly, additional copies of the references are not itted herewith, so as not to burden the file with duplicate copies of references. Examiner is respectfully requested to carefully review the references in dance with the requirements set out in the Manual of Patent Examining edure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) I upon for an earlier filing date under 35 USC 120 in which copies of the ences were previously furnished are set out below:			

In re Appln. of Saito et al. Application No. 09/706,301

	U.S. APPLI	CATIONS	Status (check one)				
US	. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED		
1.							
2.							
3.							
Statem		I hereby states that ea					
	The undersigned hereby states that each hem of information Disclosure Statement was first cited in any communication from foreign patent office in a counterpart foreign patent application not more than thre months prior to the filing of the Information Disclosure Statement.						
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.						
State	nent under 37 CF						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign pate office in a counterpart application and that this communication was not received any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filling of the Information Disclosure Statement.						
Fees							
	No fee is owed to The IDS Fee of	by the applicant(s). \$180 under 37 CFR 1.17	7(p) is enclosed	herewith.			
Meth	od of Payment of	f Fees					

. (A duplicate copy of

Attached is a check in the amount of \$
Charge Deposit Account No. 12-1216 in the amount of \$

this communication is enclosed for that purpose.)

In re Appln. of Saito et al. Application No. 09/706,301

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge \boxtimes Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 12-1216. Refund

Date: February 2, 2001

John Kilyk, Jr., Reg. No. 30/63 LEYVIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date: February 2, 2001